Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. [PDF]
PLoS ONE, 2013 Duchenne Muscular Dystrophy (DMD) is a recessive X-linked genetic disease, caused by mutations in the gene encoding dystrophin. DMD is characterized in humans and in mdx mice by a severe and progressive destruction of muscle fibers, inflammation ...
Francisco Altamirano +6 more
doaj +11 more sources
Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
Scientific Reports, 2023 Spontaneous preterm birth is the leading cause of perinatal morbidity and mortality. Tocolytics are drugs used in cases of imminent preterm birth to inhibit uterine contractions.
Bridget M. Arman +8 more
doaj +1 more source
BMC Pregnancy and Childbirth, 2022 Background Worldwide, nifedipine and atosiban are the two most commonly used tocolytic agents for the treatment of threatened preterm birth. The aim of this study was to evaluate the effectiveness of nifedipine and atosiban in an individual participant ...
Tijn M. S. van Winden +9 more
doaj +1 more source
Therapy for nifedipine-induced gingival overgrowth by saireito in rats
European Journal of Medical Research, 2009 Objective A calcium antagonist, nifedipine, causes gingival overgrowth as a side effect. It has been confirmed that the Japanese traditional medicine, Saireito, inhibits the nifedipine-induced proliferation of gingival fibroblasts in vitro.
Hattori T +5 more
doaj +1 more source
DIHYDROPYRIDINE CALCIUM ANTAGONISTS. POSITION OF NIFEDIPINE IN MODERN CARDIOLOGY PRACTICE
Рациональная фармакотерапия в кардиологии, 2016 Position of nifedipine in modern cardiology practice is highlighted. Nifedipine usage for arterial hypertension therapy , including combined one, stroke prevention, treatment of hypertensive crisis and ischemic heart disease is considered.
A. A. Garganeeva
doaj +1 more source
Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin) : study protocol for a randomized controlled trial [PDF]
, 2014 Peer reviewedPublisher ...
Anson, Ken +12 more
core +2 more sources
Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets. [PDF]
PLoS ONE, 2015 The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its
Tso-Hsiao Chen +3 more
doaj +1 more source
Pharmaceutics, 2019 Raynaud’s Phenomenon is a vascular affliction resulting in pain and blanching of the skin caused by excessive and prolonged constriction of arterioles, usually due to cold exposure.
Ellen K. Wasan +10 more
doaj +1 more source
The Inhibitory Effects of Ca2+ Channel Blocker Nifedipine on Rat Kv2.1 Potassium Channels. [PDF]
PLoS ONE, 2015 It is well documented that nifedipine, a commonly used dihydropyridine Ca2+ channel blocker, has also significant interactions with voltage-gated K+ (Kv) channels.
Xian-Tao Li +3 more
doaj +1 more source